Citi raised the firm’s price target on Arvinas (ARVN) to $21 from $18 and keeps a Buy rating on the shares. The firm increased its probability of success for ARV-102 following the “positive” Phase 1 multi-dose data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas
- Arvinas Reports Positive Phase 1 Data for ARV-102
- Arvinas presents data from Phase 1 clinical trial of ARV-102
- Arvinas price target raised to $18 from $15 at Citi
- Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines